Based on 4Q13 US Copaxone sales of $805M (#msg-96917776), the commentary in #msg-90394447 on the long-term outlook of Copaxone in the US market remains valid, IMO.
The thrice-weekly 40mg Copaxone product currently accounts for 31% of overall US Copaxone by prescription volume, according to the above PR; if we apply this 31% proportion retroactively to the 1Q14 sales number of $814M and ignore (for simplicity) the difference in ASP between the two versions of Copaxone, then 20mg daily Copaxone would have had pro forma 1Q14 sales of $814M(0.69) = $562M, or $2.25B annualized.
(Note: Actual US sales of the 20mg version during 1Q14 have not been disclosed, but they were certainly higher than the $562M pro forma number calculated above because the 40mg product was approved on 1/28/14 and gained share during the quarter.)
Other tidbits:
• There was a price increase in Jan 2014 for 20mg Copaxone.
• Total Copaxone (i.e. the two versions combined) currently has a 33.5% TRx share of the US MS market.
Market Data 
Markets 
AI
